MX2022009923A - Proteinas inmunomoduladoras variantes de ligando icos y sus usos. - Google Patents
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.Info
- Publication number
- MX2022009923A MX2022009923A MX2022009923A MX2022009923A MX2022009923A MX 2022009923 A MX2022009923 A MX 2022009923A MX 2022009923 A MX2022009923 A MX 2022009923A MX 2022009923 A MX2022009923 A MX 2022009923A MX 2022009923 A MX2022009923 A MX 2022009923A
- Authority
- MX
- Mexico
- Prior art keywords
- immunomodulatory proteins
- proteins
- icos ligand
- ligand variant
- variant immunomodulatory
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 abstract 1
- 102100034980 ICOS ligand Human genes 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente proteínas inmunomoduladoras que comprenden variantes ICOSL y ácidos nucleicos que codifican tales proteínas. Las proteínas inmunomoduladoras proporcionan utilidad terapéutica para una variedad de condiciones inmunológicas y oncológicas. Se proporcionan composiciones y métodos para hacer y usar tales proteínas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323608P | 2016-04-15 | 2016-04-15 | |
US201662394745P | 2016-09-14 | 2016-09-14 | |
US201662410842P | 2016-10-20 | 2016-10-20 | |
US201762472568P | 2017-03-16 | 2017-03-16 | |
US201762475162P | 2017-03-22 | 2017-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009923A true MX2022009923A (es) | 2022-09-09 |
Family
ID=60042799
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012472A MX2018012472A (es) | 2016-04-15 | 2017-04-14 | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
MX2022009923A MX2022009923A (es) | 2016-04-15 | 2018-10-11 | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012472A MX2018012472A (es) | 2016-04-15 | 2017-04-14 | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10882914B2 (es) |
EP (1) | EP3442999A2 (es) |
JP (2) | JP7058609B2 (es) |
KR (3) | KR20230051601A (es) |
CN (1) | CN110088126A (es) |
AU (2) | AU2017250358B2 (es) |
BR (1) | BR112018070934A2 (es) |
CA (1) | CA3019199A1 (es) |
IL (1) | IL262365A (es) |
MA (1) | MA43551A (es) |
MX (2) | MX2018012472A (es) |
SG (1) | SG11201808457PA (es) |
WO (1) | WO2017181148A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11319359B2 (en) | 2015-04-17 | 2022-05-03 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
EP3371208A1 (en) | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
EP3529361B1 (en) * | 2016-10-20 | 2021-03-24 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
EP3634466A4 (en) * | 2017-06-06 | 2021-03-24 | Relinia, Inc. | MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
JP7282760B2 (ja) * | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
JP2021519072A (ja) * | 2018-03-27 | 2021-08-10 | システィミューン, インク.Systimmune, Inc. | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
KR20210024488A (ko) * | 2018-05-24 | 2021-03-05 | 러쉬 유니버시티 메디컬 센터 | 신장 치료로 사용을 위한 icosl |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
WO2020041541A2 (en) | 2018-08-23 | 2020-02-27 | Seattle Genetics, Inc. | Anti-tigit antibodies |
EP3914274A4 (en) * | 2019-01-24 | 2022-11-16 | University of Central Florida Research Foundation, Inc. | COMPOSITIONS AND METHODS FOR STIMULATION OF NATURAL KILLER CELLS |
KR20220035032A (ko) * | 2019-04-17 | 2022-03-21 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도 |
JP2023515554A (ja) * | 2020-02-25 | 2023-04-13 | モメンタ ファーマシューティカルズ インコーポレイテッド | グリカンのシアリル化のための酵素 |
CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
WO2023147564A2 (en) * | 2022-01-28 | 2023-08-03 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
WO2023168436A1 (en) * | 2022-03-03 | 2023-09-07 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
KR20230155960A (ko) * | 2022-05-03 | 2023-11-13 | 고려대학교 산학협력단 | Icos와의 결합력이 향상된 icos-l 변이체 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
AU674492B2 (en) | 1991-05-06 | 1997-01-02 | United States of America, as represented by the Department of Health and Human Services, The | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6361770B1 (en) | 1994-09-23 | 2002-03-26 | University Of British Columbia | Method of enhancing expression of MHC class I molecules bearing endogenous peptides |
EP0784483B1 (en) | 1994-10-03 | 2000-11-29 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
ES2317646T3 (es) | 1995-09-08 | 2009-04-16 | Genzyme Corporation | Vectores aav mejorados para terapia genica. |
US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
AU8828598A (en) | 1997-08-15 | 1999-03-08 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
IL141044A0 (en) | 1998-08-07 | 2002-02-10 | Univ Washington | Innunological herpes simplex virus antigens and methods for use thereof |
CA2348382C (en) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Chimeric parvovirus vectors and methods of making and administering the same |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
DK1916258T3 (da) | 1999-08-09 | 2014-07-28 | Genzyme Corp | Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar |
WO2001021796A2 (en) | 1999-09-21 | 2001-03-29 | Genetics Institute, Inc. | Gl50 molecules and uses therefor |
US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
WO2001045737A2 (en) | 1999-12-22 | 2001-06-28 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
DK1252323T3 (da) | 2000-01-21 | 2006-04-03 | Biovex Ltd | Virus-stammer til den onkolytiske behandling af cancer |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
AU2001271731A1 (en) | 2000-06-28 | 2002-01-08 | Dana-Farber Cancer Institute, Inc. | PD-L2 molecules: novel PD-1 ligands and uses therefor |
US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
EP1385466B1 (en) | 2001-05-11 | 2011-03-09 | Wellstat Biologics Corporation | Oncolytic virus therapy |
EP1411880B1 (en) | 2001-07-11 | 2018-04-25 | University of Miami | Recombinant vsv for the treatment of tumor cells |
CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
JP4364643B2 (ja) | 2001-11-30 | 2009-11-18 | アメリカ合衆国 | 前立腺特異抗原のペプチドアゴニストおよびその使用 |
US7235631B2 (en) | 2002-02-07 | 2007-06-26 | Mayo Foundation For Medical Education And Research | ICOS mutants |
JP2005521398A (ja) | 2002-03-27 | 2005-07-21 | ベイラー カレッジ オブ メディスン | 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス |
US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
WO2004000209A2 (en) | 2002-06-21 | 2003-12-31 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
CN1820078A (zh) | 2002-09-09 | 2006-08-16 | 田纳西大学研究基金会 | 弹状病毒的重组突变体及其应用方法 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
DK1606411T3 (da) | 2003-03-27 | 2009-03-30 | Ottawa Health Research Inst | Mutant vesikulær stomatitis-vira og anvendelse deraf |
JP3934673B1 (ja) | 2003-06-18 | 2007-06-20 | ジェネラックス・コーポレイション | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
EP2292779B1 (en) | 2003-09-30 | 2016-11-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
US20070003520A1 (en) | 2003-11-17 | 2007-01-04 | Brown Susanne M | Mutant viruses |
GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
NZ578643A (en) | 2004-04-13 | 2010-11-26 | Hoffmann La Roche | Anti-P-selectin antibodies |
WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2006060314A2 (en) | 2004-12-01 | 2006-06-08 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
WO2006130855A2 (en) | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
EP2526774A3 (en) | 2006-07-21 | 2013-03-06 | California Institute of Technology | Targeted gene delivery for dendritic cell vaccination |
EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
JP5213075B2 (ja) | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および/または処置のための微生物 |
AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
EP2202297B1 (en) | 2007-07-18 | 2014-05-14 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
EP2212696B1 (en) | 2007-10-25 | 2013-12-04 | Genelux Corporation | Systems and methods for viral therapy |
AU2008329518A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof |
RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
US20120052003A9 (en) | 2008-05-16 | 2012-03-01 | Szalay Aladar A | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
SI2770061T1 (sl) | 2009-07-24 | 2019-02-28 | Immune Design Corp. | Neintegrirani lentiviralni vektorji |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
US9133436B2 (en) * | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
TW201134481A (en) | 2010-03-12 | 2011-10-16 | Abbott Biotherapeutics Corp | CTLA4 proteins and their uses |
CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
SI2726101T1 (sl) | 2011-06-30 | 2018-12-31 | Genzyme Corporation | Inhibitorji aktivacije T-celic |
WO2013001517A1 (en) * | 2011-06-30 | 2013-01-03 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
MX366864B (es) | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
PL3207938T3 (pl) | 2012-05-11 | 2020-07-13 | Medimmune Limited | Warianty CTLA-4 |
RS58528B1 (sr) * | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
KR20150128796A (ko) | 2013-03-15 | 2015-11-18 | 바이오젠 엠에이 인코포레이티드 | 항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방 |
WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
WO2014207748A1 (en) | 2013-06-27 | 2014-12-31 | Alexander Biro | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
EP3835318A1 (en) | 2014-01-15 | 2021-06-16 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
EP3169341B1 (en) | 2014-07-16 | 2019-06-05 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
US10800830B2 (en) | 2014-08-08 | 2020-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
WO2016073704A1 (en) | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
WO2016164428A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
US11319359B2 (en) | 2015-04-17 | 2022-05-03 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
EP3328363A4 (en) | 2015-07-31 | 2019-08-21 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS OF IMMUNOMODULATION |
EP3328377A4 (en) | 2015-07-31 | 2019-03-13 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGICAL THERAPIES |
CA2997217A1 (en) | 2015-09-14 | 2017-03-23 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
HRP20221041T1 (hr) | 2015-10-02 | 2022-11-11 | Symphogen A/S | Anti-pd-1 antitijela i sastavi |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
EP3529361B1 (en) | 2016-10-20 | 2021-03-24 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
-
2017
- 2017-04-14 BR BR112018070934-4A patent/BR112018070934A2/pt unknown
- 2017-04-14 MX MX2018012472A patent/MX2018012472A/es unknown
- 2017-04-14 AU AU2017250358A patent/AU2017250358B2/en active Active
- 2017-04-14 WO PCT/US2017/027811 patent/WO2017181148A2/en active Application Filing
- 2017-04-14 US US15/488,409 patent/US10882914B2/en active Active
- 2017-04-14 SG SG11201808457PA patent/SG11201808457PA/en unknown
- 2017-04-14 EP EP17733114.7A patent/EP3442999A2/en active Pending
- 2017-04-14 KR KR1020237011244A patent/KR20230051601A/ko not_active Application Discontinuation
- 2017-04-14 CN CN201780036984.0A patent/CN110088126A/zh active Pending
- 2017-04-14 KR KR1020187033049A patent/KR102536850B1/ko active IP Right Grant
- 2017-04-14 KR KR1020237011245A patent/KR20230051602A/ko active Application Filing
- 2017-04-14 JP JP2018554101A patent/JP7058609B2/ja active Active
- 2017-04-14 MA MA043551A patent/MA43551A/fr unknown
- 2017-04-14 CA CA3019199A patent/CA3019199A1/en active Pending
-
2018
- 2018-10-11 MX MX2022009923A patent/MX2022009923A/es unknown
- 2018-10-14 IL IL262365A patent/IL262365A/en unknown
-
2020
- 2020-11-24 US US17/103,807 patent/US20210188995A1/en active Pending
-
2022
- 2022-01-28 JP JP2022012270A patent/JP2022064959A/ja active Pending
-
2023
- 2023-05-02 AU AU2023202718A patent/AU2023202718A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170320959A1 (en) | 2017-11-09 |
AU2023202718A1 (en) | 2023-05-18 |
CA3019199A1 (en) | 2017-10-19 |
KR20230051602A (ko) | 2023-04-18 |
SG11201808457PA (en) | 2018-10-30 |
US10882914B2 (en) | 2021-01-05 |
WO2017181148A2 (en) | 2017-10-19 |
MX2018012472A (es) | 2019-08-12 |
AU2017250358B2 (en) | 2023-06-01 |
KR20230051601A (ko) | 2023-04-18 |
BR112018070934A2 (pt) | 2019-02-26 |
US20210188995A1 (en) | 2021-06-24 |
WO2017181148A3 (en) | 2018-02-01 |
KR102536850B1 (ko) | 2023-05-26 |
JP7058609B2 (ja) | 2022-04-22 |
MA43551A (fr) | 2018-11-07 |
NZ746741A (en) | 2023-12-22 |
KR20190005879A (ko) | 2019-01-16 |
EP3442999A2 (en) | 2019-02-20 |
CN110088126A (zh) | 2019-08-02 |
AU2017250358A1 (en) | 2018-10-18 |
IL262365A (en) | 2018-11-29 |
JP2022064959A (ja) | 2022-04-26 |
JP2019514361A (ja) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009923A (es) | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. | |
NZ746934A (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
PH12020550449A1 (en) | Variant icos ligand immunomodulatory proteins and related compositions and methods | |
NZ756395A (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
EP4306537A3 (en) | Pd-l1 variant immunomodulatory proteins and uses thereof | |
WO2016168771A3 (en) | Immunomodulatory proteins with tunable affinities | |
MX2017009538A (es) | Antigenos de citomegalovirus y su uso. | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
SG10201914126RA (en) | Anti-ox40 antibodies and their uses | |
WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
EP3217807A4 (en) | Methods and compositions for egg white protein production | |
EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
MY181175A (en) | Therapeutic hpv16 vaccines | |
EP3368556A4 (en) | INNOVATIVE POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
MY191539A (en) | Streptococcal vaccine | |
EP3094718A4 (en) | Microorganisms for the enhanced production of amino acids and related methods | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
EP3369741A4 (en) | NEW PEPTIDE | |
MX2021012607A (es) | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. | |
EP3305802A4 (en) | NEW PEPTIDE AND COMPOSITION CONTAINING SAME | |
EP3210621A4 (en) | Micellar polypeptide vaccine having pegylated phospholipids as carrier | |
WO2016009401A3 (en) | Preparation of tedizolid phosphate | |
EP3525805A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | |
WO2015134332A3 (en) | Recombinant isfahan viral vectors | |
MX2020012893A (es) | Formulaciones de proteinas. |